OBIO vs. CLPT, SMLR, NNOX, SMTI, STIM, SNWV, ZIMV, NVRO, TCMD, and SKIN
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include ClearPoint Neuro (CLPT), Semler Scientific (SMLR), Nano-X Imaging (NNOX), Sanara MedTech (SMTI), Neuronetics (STIM), SANUWAVE Health (SNWV), ZimVie (ZIMV), Nevro (NVRO), Tactile Systems Technology (TCMD), and Beauty Health (SKIN). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs.
Orchestra BioMed (NASDAQ:OBIO) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
ClearPoint Neuro has higher revenue and earnings than Orchestra BioMed. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
ClearPoint Neuro received 4 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 89.29% of users gave ClearPoint Neuro an outperform vote.
ClearPoint Neuro has a net margin of -59.64% compared to Orchestra BioMed's net margin of -2,179.33%. ClearPoint Neuro's return on equity of -62.10% beat Orchestra BioMed's return on equity.
53.5% of Orchestra BioMed shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by company insiders. Comparatively, 7.0% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Orchestra BioMed presently has a consensus target price of $14.20, indicating a potential upside of 418.25%. ClearPoint Neuro has a consensus target price of $25.00, indicating a potential upside of 105.59%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than ClearPoint Neuro.
In the previous week, ClearPoint Neuro had 5 more articles in the media than Orchestra BioMed. MarketBeat recorded 9 mentions for ClearPoint Neuro and 4 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.50 beat ClearPoint Neuro's score of 0.30 indicating that Orchestra BioMed is being referred to more favorably in the media.
Orchestra BioMed has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Summary
Orchestra BioMed beats ClearPoint Neuro on 10 of the 19 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy OBIO Stock Free OBIO Stock Alerts